Tetramethylpyrazine reduces prostate cancer malignancy through inactivation of the DPP10 ‑AS1/CBP/FOXM1 signaling pathway.

In conclusion, the present study showed that TMP may be a promising treatment agent for PCa and lncRNA DPP10‑AS1 may be a promising therapeutic target for TMP treatment. PMID: 32319592 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32319592?dopt=Abstract

Source: International Journal of Oncology - March 31, 2020 Category: Cancer & Oncology Authors: Zhou Y, Zhou Z, Ji Z, Yan W, Li H, Yu X Tags: Int J Oncol Source Type: research